Brexpiprazole Discontinuation Protocol
Rexulti (brexpiprazole) should generally not be stopped abruptly; discontinuation should be managed by the prescribing clinician with a gradual dose reduction to reduce the risk of symptom recurrence or discontinuation effects. [1], [2]
Discontinuation Approach in Routine Clinical Situations
Gradual tapering is recommended rather than abrupt cessation when discontinuation is planned for stability-related reasons. [2], [3] Dose reductions should be individualized to the patient’s psychiatric history, current stability, and prior relapse pattern. [2] Close monitoring for recurrence of the treated condition should be performed during dose reduction. [2], [3]
Immediate Discontinuation Indications
If neuroleptic malignant syndrome is suspected, immediate discontinuation of Rexulti is recommended with intensive symptomatic treatment and close monitoring. [1]
Taper Timing When Concomitant CYP3A4 Inducer Is Discontinued
If a concomitant strong CYP3A4 inducer is discontinued, the Rexulti dose should be reduced back to the original level over 1 to 2 weeks. [1]
Monitoring for Emergent Withdrawal-Like Symptoms and Relapse
Monitoring should include recurrence or worsening of the underlying psychiatric symptoms during and after dose reduction. [2], [3] If clinically significant worsening occurs, consideration should be given to changing the therapeutic regimen, including possible discontinuation decisions made in conjunction with the clinician. [1]
Practical Switching Considerations After Discontinuation
When discontinuation is pursued due to inadequate response or adverse effects, the therapeutic regimen should be reassessed during the discontinuation period. [1], [2] A transition plan should include the alternative treatment timing since discontinuation is managed by the prescribing clinician rather than by patient-directed abrupt stopping. [2], [3]
Common Pitfalls to Avoid
Abrupt stopping without clinician guidance should be avoided because dose tapering is recommended rather than abrupt cessation. [2], [3] Discontinuation should not be treated as a single event; relapse monitoring is required during dose reduction. [2], [3]
Special Populations Requiring Heightened Clinical Monitoring During Discontinuation
Patients with a history of major psychiatric illness or prior discontinuation-related destabilization should be monitored closely during tapering. [2] Patients at risk for serious adverse reactions should be monitored for clinical deterioration that would warrant reassessment of continued treatment decisions. [1]